Neonatal Unit, The Royal Women's Hospital, Parkville, Victoria, Australia.
J Perinatol. 2011 Dec;31(12):799-801. doi: 10.1038/jp.2011.38.
Management of atelectasis and lung collapse in ventilated neonates remains a common challenge in the neonatal intensive care unit. Recombinant human DNase (rhDNase) is an established treatment of atelectasis in cystic fibrosis and its use is also reported in the management of asthma, respiratory syncitial virus bronchiolitis and bronchiectasis to liquefy sputum and aid its clearance from the lungs. We report the use of rhDNase in a subgroup of ventilated neonates with severe end-stage respiratory failure and atelectasis. Three of the four patients showed clinical improvement. A previously undiagnosed lung anomaly was subsequently identified in the fourth patient. Future randomized studies could examine any potential benefits of this emerging therapy.
在新生儿重症监护病房中，机械通气新生儿的肺不张和肺萎陷的管理仍然是一个常见的挑战。重组人 DNA 酶（rhDNase）是囊性纤维化肺不张的既定治疗方法，其在哮喘、呼吸道合胞病毒细支气管炎和支气管扩张症的管理中的应用也有报道，以液化痰液并帮助其从肺部清除。我们报告了 rhDNase 在一组患有严重终末期呼吸衰竭和肺不张的机械通气新生儿中的应用。这 4 名患者中的 3 名显示出临床改善。第四例患者随后发现了一种先前未诊断出的肺部异常。未来的随机研究可以检查这种新兴治疗方法的任何潜在益处。
